Highlights • Metformin (AMPK activator) and baicalin (CPT1A activator) improved mitochondrial function. • Both drugs reduced kidney fibrosis in different animal models of lung and kidney injury, key target organs of COVID-19. • AMPK/ACC activation decreased TGF-β-induced fibrosis, apoptosis and inflammation markers in lung and renal epithelial cells. • COVID-19 patients on previous treatment with Metformin showed reduced time of hospitalization and needed of intensive care.
【저자키워드】 COVID-19, Inflammation, Mitochondria, fibrosis, metabolism,